ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0303

Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2

Laura K. Ferris1, Jerry Bagel2, Yu-Huei Huang3, Andrew E. Pink4, Stephen K. Tyring5, Georgios Kokolakis6, Amy M. DeLozier7, Daniel Kakaley8, Shu Li9, Yaung-Kaung Shen10, Takayuki Ota7 and Robert Bissonnette11, 1University of Pittsburgh, Pittsburgh, PA, 2Psoriasis Treatment Center of Central NJ, East Windsor, NJ, 3Chang Gung Memorial Hospital and Chang Gung University, Linkou, Taoyuan City, Taiwan (Republic of China), 4NHS Foundation Trust Great Maze Pond, London, United Kingdom, 5Center for Clinical Studies, Webster, TX, 6Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 7Janssen Research & Development, LLC, San Diego, CA, 8Janssen Scientific Affairs, LLC, Horsham, PA, 9Janssen Research & Development, LLC, Spring House, PA/San Diego, CA, 10Janssen Research & Development, LLC, Spring House, PA, 11Innovaderm Research, Montreal, QC, Canada

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, clinical trial, Interleukins, Randomized Trial, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: JNJ-77242113, a targeted oral peptide, inhibits IL-23 signaling by binding the IL-23 receptor. At all doses, JNJ-77242113 showed superior efficacy at Week 16 versus placebo (PBO) in moderate-to-severe psoriasis in FRONTIER-1.1 FRONTIER-2 was a multicenter, long-term extension, double-blind, dose-ranging, phase 2b study evaluating efficacy and safety of JNJ-77242113 in adults with moderate-to-severe plaque psoriasis who were candidates for systemic treatment or phototherapy.

Methods: FRONTIER-1 randomized patients 1:1:1:1:1:1 to JNJ-77242113 25 mg once daily (QD), 25 mg twice daily (BID), 50 mg QD, 100 mg QD, 100 mg BID, or PBO through Week 16. In FRONTIER-2, patients completing FRONTIER-1 (at Week 16) continued their assigned dose through Week 52; those randomized to PBO crossed over to 100 mg QD (PBO→100 mg QD). The primary endpoint was the proportion of patients achieving ≥75% improvement in Psoriasis Area and Severity Index (PASI 75) at Week 52. Response rates were estimated using non-responder imputation and FRONTIER-1 baseline data.

Results: Response rates among JNJ-77242113-treated patients from FRONTIER-1 were maintained, across dose groups, through Week 52 (Figure 1). Patients who crossed over to JNJ-77242113 from PBO at Week 16 (PBO→100 mg QD) had substantially higher response rates at Week 52 (Figure 1). At Week 52, proportions of patients achieving PASI 75 were JNJ-77242113: 25 mg QD 48.8%, 25 mg BID 58.5%, 50 mg QD 69.8%, 100 mg QD 65.1%, 100 mg BID 76.2%, and PBO→100 mg QD 65.7%; respective rates for ≥90% improvement in PASI (PASI 90)/complete clearance (PASI 100) were 27.9%/14.0%, 36.6%/17.1%, 41.9%/20.9%, 51.2%/25.6%, 64.3%/40.5%, and 57.1%/34.3%. Proportions of patients achieving an Investigator’s Global Assessment (IGA) score of 0/1 or 0 were JNJ-77242113 at Week 52 were: 25 mg QD 37.2%/14.0%, 25 mg BID 46.3%/19.5%, 50 mg QD 60.5%/23.3%, 100 mg QD 60.5%/30.2%, 100 mg BID 73.8%/42.9%, and PBO→100 mg QD 65.7%/31.4%. Approximately 90% of patients receiving JNJ-77242113 100 mg BID who had achieved a PASI 75, PASI 90, or IGA 0/1 response at Week 16 maintained the response at Week 52 (Figure 2). Across dose groups, 58.6% of patients experienced adverse events (AEs), with no evidence of a dose-dependent increase in AEs, including gastrointestinal disorders. The proportion of patients with serious AEs through Week 52 was 4% and all serious AEs were considered unrelated to study treatment.

Conclusion: In psoriasis patients receiving JNJ-77242113, the first targeted oral peptide to selectively block IL-23 pathway signaling, rates of near-complete/complete skin clearance from FRONTIER-11 were maintained through Week 52; the highest response rates were seen in patients randomized to JNJ-77242113 100 mg BID. Among patients who had achieved a PASI or IGA response at Week 16, responses were maintained in substantial proportions of patients at Week 52. Consistent with prior studies, no safety signals were identified. 

Reference:

 1.      Bissonnette R, et al. N Engl J Med. 2024;390:510-21.

Supporting image 1

Supporting image 2


Disclosures: L. K. Ferris: AbbVie, 5, 6, 12, Investigator, Acelyrin, 12, Investigator, Amgen, 2, 12, Investigator, Apogee, 2, 12, Investigator, Arcutis, 2, 6, 12, Investigator, Aristea, 12, Investigator, Boehringer-Ingelheim, 2, 6, 12, Investigator, Bristol-Myers Squibb, 2, 6, 12, Investigator, Cara Therapeutics, 2, 12, Investigator, Castle Biosciences, 12, Investigator, DermTech, 2, 12, Investigator, Eli Lilly, 12, Investigator, Galderma, 12, Investigator, GRAIL, 12, Investigator, Incyte, 12, Investigator, Janssen, 2, 12, Investigator, Leo Pharma, 2, 12, Investigator, Moberg, 12, Investigator, Mobius, 12, Investigator, Novartis, 2, 12, Investigator, Regeneron, 2, 6, 12, investigator, SkinAnalytics, 12, Investigator, Takeda, 2, 12, Investigator, UCB, 12, Investigator; J. Bagel: AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Arcutis, 5, Boehringer Ingelheim, 5, Bristol Myers Squibb, 5, Celgene, 2, 5, 6, CorEvitas, 5, Dermavant, 5, Dermira/UCB, 5, Eli Lilly, 2, 5, 6, Glenmark, 5, Janssen, 2, 5, 6, Kadmon, 5, Leo Pharma, 2, 5, 6, Lycera, 5, Menlo, 5, Novartis, 2, 5, 6, Pfizer, 5, Regeneron, 5, Sun, 2, 5, 6, Taro, 5, Valeant, 2, 5, 6; Y. Huang: AbbVie, 2, 6, 12, Conducted clinical trials, Bristol Myers Squibb, 2, 6, 12, Conducted clinical trials, Celgene, 2, 6, 12, Conducted clinical trials, Janssen-Cilag Pharmaceuticals, 2, 6, 12, Conducted clinical trials, Novartis, 2, 6, 12, Conducted clinical trials, Pfizer Pharmaceuticals, 2, 6, 12, Conducted clinical trials; A. Pink: AbbVie, 1, 2, 6, 12, Investigator, Almirall, 1, 2, 6, BI, 1, 2, 6, 12, Investigator, BMS, 1, 2, 6, 12, Investigator, Galderma, 1, 2, 6, 12, Investigator, Janssen, 1, 2, 6, Leo, 1, 2, 6, 12, Investigator, Lilly, 1, 2, 6, Novartis, 1, 2, 6, Pfizer, 1, 2, 6, 12, Investigator, Sanofi, 1, 2, 6, 12, Investigator, UCB, 1, 2, 6; S. Tyring: AbbVie, 2, 5, 6, Agenus, 2, 5, 6, AiCuris GmBH, 2, 5, 6, Almirall, 2, 5, 6, Amgen, 2, 5, 6, Bayer, 2, 5, 6, BMS, 2, 5, 6, Demira, 2, 5, 6, Dr Reddy's Laboratory, 2, 5, 6, Eli Lilly, 2, 5, 6, Foamix Pharma, 2, 5, 6, Galderma, 2, 5, 6, Genocea Biosciences, 2, 5, 6, GlaxoSmithKline Immunology, 2, 5, 6, Glenmark Pharma, 2, 5, 6, IQVIA, 2, 5, 6, Janssen Research & Development, 2, 5, 6, Kinksa Pharma, 2, 5, 6, LEO Laboratories, 2, 5, 6, Menlo Therapeutics, 2, 5, 6, Merck, 2, 5, 6, Novartis, 2, 5, 6, Nycomed Amersham, 2, 5, 6, Parexel, 2, 5, 6, Quntiles Pharma, 2, 5, 6, Regeneron Pharma, 2, 5, 6, Sanofi, 2, 5, 6, Trevi Therapeutics, 2, 5, 6, UCB, 2, 5, 6, Vical, 2, 5, 6; G. Kokolakis: Abbott, 1, 6, AbbVie, 1, 6, Actelion Pharmaceuticals, 1, 6, Amgen, 1, 6, Basilea Pharmaceutica, 1, 6, Bayer, 1, 6, Biogen IDEC, 1, 6, Boehringer, 1, 6, Bristol-Myers Squibb, 1, 6, Celgene, 1, 6, Hexal, 1, 6, Janssen-Cilag, 1, 6, LEO Pharma, 1, 6, Lilly, 1, 6, MSD, 1, 6, Mylan, 1, 6, Novartis, 1, 6, Parexel, 1, 6, Pfizer, 1, 6, Sanofi-Aventis, 1, 6, Sharpe and Dohme, 1, 6, Takeda, 1, 6, UCB, 1, 6; A. DeLozier: Janssen, 3, Johnson & Johnson, 11; D. Kakaley: Janssen, 3, Johnson & Johnson, 11; S. Li: Janssen, 3, Johnson & Johnson, 11; Y. Shen: Janssen, 3, Johnson & Johnson, 11; T. Ota: Janssen, 3, Johnson & Johnson, 11; R. Bissonnette: AbbVie, 1, 2, 5, 6, 12, Investigator, Alumis, 1, 2, 5, 6, 12, Investigator, Amgen, 1, 2, 5, 6, 12, Investigator, AnaptysBio, 1, 2, 5, 6, 12, Investigator, Bausch Health, 1, 2, 5, 6, 12, Investigator, BMS/Celgene, 1, 2, 5, 6, 12, Investigator, Boston, 1, 2, 5, 6, 12, Investigator, Dermavant, 1, 2, 5, 6, 12, Investigator, Eli Lilly, 1, 2, 5, 6, 12, Investigator, Innovaderm Research, 3, 11, Janssen, 1, 2, 5, 6, 12, Investigator, LEO Pharma, 1, 2, 5, 6, 12, Investigator, Nimbus, 1, 2, 5, 6, 12, Investigator, Novartis, 1, 2, 5, 6, 12, Investigator, Pfizer, 1, 2, 5, 6, 12, Investigator, Regeneron, 1, 2, 5, 6, 12, Investigator, UCB, 1, 2, 5, 6, 12, Investigator, VentyxBio, 1, 2, 5, 6, 12, Investigator, Xencor, 1, 2, 5, 6, 12, Investigator.

To cite this abstract in AMA style:

K. Ferris L, Bagel J, Huang Y, Pink A, Tyring S, Kokolakis G, DeLozier A, Kakaley D, Li S, Shen Y, Ota T, Bissonnette R. Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2 [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/phase-2b-long-term-extension-dose-ranging-study-of-oral-jnj-77242113-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-frontier-2/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/phase-2b-long-term-extension-dose-ranging-study-of-oral-jnj-77242113-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-frontier-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology